These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10715145)

  • 1. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.
    Talley JJ; Brown DL; Carter JS; Graneto MJ; Koboldt CM; Masferrer JL; Perkins WE; Rogers RS; Shaffer AF; Zhang YY; Zweifel BS; Seibert K
    J Med Chem; 2000 Mar; 43(5):775-7. PubMed ID: 10715145
    [No Abstract]   [Full Text] [Related]  

  • 2. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
    Gierse JK; Zhang Y; Hood WF; Walker MC; Trigg JS; Maziasz TJ; Koboldt CM; Muhammad JL; Zweifel BS; Masferrer JL; Isakson PC; Seibert K
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration.
    Talley JJ; Bertenshaw SR; Brown DL; Carter JS; Graneto MJ; Kellogg MS; Koboldt CM; Yuan J; Zhang YY; Seibert K
    J Med Chem; 2000 May; 43(9):1661-3. PubMed ID: 10794682
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.
    Almansa C; Alfón J; de Arriba AF; Cavalcanti FL; Escamilla I; Gómez LA; Miralles A; Soliva R; Bartrolí J; Carceller E; Merlos M; García-Rafanell J
    J Med Chem; 2003 Jul; 46(16):3463-75. PubMed ID: 12877584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2.
    Khanna IK; Weier RM; Yu Y; Collins PW; Miyashiro JM; Koboldt CM; Veenhuizen AW; Currie JL; Seibert K; Isakson PC
    J Med Chem; 1997 May; 40(11):1619-33. PubMed ID: 9171872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.
    Khanna IK; Weier RM; Yu Y; Xu XD; Koszyk FJ; Collins PW; Koboldt CM; Veenhuizen AW; Perkins WE; Casler JJ; Masferrer JL; Zhang YY; Gregory SA; Seibert K; Isakson PC
    J Med Chem; 1997 May; 40(11):1634-47. PubMed ID: 9171873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human and rat cyclooxygenases are pharmacologically distinct.
    Ramesha CS
    Adv Exp Med Biol; 1997; 407():67-71. PubMed ID: 9321933
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemical and biological investigation of N-hydroxy-valdecoxib: An active metabolite of valdecoxib.
    Erdélyi P; Fodor T; Varga AK; Czugler M; Gere A; Fischer J
    Bioorg Med Chem; 2008 May; 16(9):5322-30. PubMed ID: 18353655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells.
    Berg J; Fellier H; Christoph T; Kremminger P; Hartmann M; Blaschke H; Rovensky F; Towart R; Stimmeder D
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Apr; 361(4):363-72. PubMed ID: 10763850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.
    Almansa C; de Arriba AF; Cavalcanti FL; Gómez LA; Miralles A; Merlos M; García-Rafanell J; Forn J
    J Med Chem; 2001 Feb; 44(3):350-61. PubMed ID: 11462976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal.
    Di Nunno L; Vitale P; Scilimati A; Tacconelli S; Patrignani P
    J Med Chem; 2004 Sep; 47(20):4881-90. PubMed ID: 15369392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.
    Khanna IK; Yu Y; Huff RM; Weier RM; Xu X; Koszyk FJ; Collins PW; Cogburn JN; Isakson PC; Koboldt CM; Masferrer JL; Perkins WE; Seibert K; Veenhuizen AW; Yuan J; Yang DC; Zhang YY
    J Med Chem; 2000 Aug; 43(16):3168-85. PubMed ID: 10956225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibitors--is there cause for concern?
    Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
    Nat Med; 1999 Jun; 5(6):621-2. PubMed ID: 10371498
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.
    Inagaki M; Tsuri T; Jyoyama H; Ono T; Yamada K; Kobayashi M; Hori Y; Arimura A; Yasui K; Ohno K; Kakudo S; Koizumi K; Suzuki R; Kawai S; Kato M; Matsumoto S
    J Med Chem; 2000 May; 43(10):2040-8. PubMed ID: 10821716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory effect of FR140423, a novel selective cyclo-oxygenase-2 inhibitor, in rat adjuvant arthritis without gastrointestinal side effects.
    Ochi T; Goto T
    J Pharm Pharmacol; 2000 May; 52(5):553-60. PubMed ID: 10864144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cox-2 inhibitors.
    Strassels S
    J Mass Dent Soc; 1999; 48(3):43-4. PubMed ID: 10808349
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice.
    Lipsky PE; Abramson SB; Breedveld FC; Brook P; Burmester R; Buttgereit F; Cannon GW; Catella-Lawson F; Crofford LJ; Doherty M; Dougados M; DuBois RN; Froelich J; Garcia Rodriguez LA; Gibofsky A; Hernandez-Diaz S; Hochberg MC; Krause A; Liang MH; Machold K; Peloso PM; Raisz LG; Schayes B; Scheiman JM; Simon LS; Smolen J
    J Rheumatol; 2000 Jun; 27(6):1338-40. PubMed ID: 10852251
    [No Abstract]   [Full Text] [Related]  

  • 18. Valdecoxib.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(3):116-25. PubMed ID: 12227215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of NSAID therapy: selective COX-2 inhibitors.
    Vane JR; Botting RM
    Int J Clin Pract; 2000; 54(1):7-9. PubMed ID: 10750251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.